Johns Hopkins ABX Guide
Vowst
INDICATIONS
FDA
FDA
- Vowst is indicated for preventingClostridioides difficile infection (CDI) recurrence in patients ≥ 18 years of age following antibacterial treatment for recurrent CDI.
- Vowst should NOT be given for the treatment of active CDI.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 10, 2023
Citation
Dzintars, Kathryn . "Vowst." Johns Hopkins ABX Guide, The Johns Hopkins University, 2023. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540784/all/Vowst.
Dzintars K. Vowst. Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540784/all/Vowst. Accessed November 21, 2024.
Dzintars, K. (2023). Vowst. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540784/all/Vowst
Dzintars K. Vowst [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. [cited 2024 November 21]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540784/all/Vowst.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Vowst
ID - 540784
A1 - Dzintars,Kathryn ,Pharm.D., BCPS
Y1 - 2023/10/10/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540784/all/Vowst
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
